Management of bisphosphonate-associated osteonecrosis: Pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 110, Issue 5, 2010, Pages 593-596

  Epstein, Matthew S ^a   Wicknick, Fredrick W ^b   Epstein, Joel B ^c   Berenson, James R ^d   Gorsky, Meir ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Oral and Maxillofacial Surgery   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CHLORHEXIDINE; MOUTHWASH; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; SCAVENGER; TOPICAL ANTIINFECTIVE AGENT;

AGED; ARTICLE; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW DISEASE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; ANTI-INFECTIVE AGENTS, LOCAL; ANTIOXIDANTS; BONE DENSITY CONSERVATION AGENTS; CHLORHEXIDINE; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; FREE RADICAL SCAVENGERS; HUMANS; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; MOUTHWASHES; OSTEONECROSIS; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 77958082644     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2010.05.067     Document Type: Article

References (26)

1. C.A. Migliorati, M.A. Siegel, and L.S. Elting Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment Lancet Oncol 7 2006 508 514
2. M.D. Michaelson, and M.R. Smith Bisphosphonates for treatment and prevention of bone metastases J Clin Oncol 23 2005 8219 8224
3. V.M. Cartsos, S. Zhu, and A.I. Zavras Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people J Am Dent Assoc 139 2008 23 30
4. J.T. Grbic, R. Landesberg, S.Q. Lin, P. Mesenbrink, I.R. Reid, and P.C. Leung Health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial research group Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial J Am Dent Assoc 139 2008 32 40
5. A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, and A. Rapoport Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors J Clin Oncol 24 2006 945 952
6. M. Khamaisi, E. Regev, N. Yarom, B. Avni, E. Leitersdorf, and I. Raz Possible association between diabetes and bisphosphonate-related jaw osteonecrosis J Clin Endocrinol Metab 92 2007 1172 1175
7. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws J Oral Maxillofac Surg 65 2007 369 376
8. C.A. Migliorati, J. Casiglia, J. Epstein, P.L. Jacobsen, M.A. Siegel, and S.B. Woo Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper J Am Dent Assoc 136 2005 1658 1668
9. B.J. Edwards, J.W. Hellstein, P.L. Jacobsen, S. Kaltman, A. Mariotti, C.A. Migliorati American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs J Am Dent Assoc 139 2008 1674 1677
10. B.J. Edwards, J.W. Hellstein, P.L. Jacobsen, S. Kaltman, A. Mariotti, and C.A. Migliorati Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs J Am Dent Assoc 139 2008 1674 1677
11. M.S. Teng, and N.D. Futran Osteoradionecrosis of the mandible Curr Opin Otolaryngol Head Neck Surg 13 2005 217 221
12. S. Delanian Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis J Clin Oncol 23 2005 8570 8579
13. S. Delanian, J. Depondt, and J.L. Lefaix Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial Head Neck 27 2005 114 123
14. A. Altenburg, M.B. Abdel-Naser, H. Seeber, M. Abdallah, and C.C. Zouboulis Practical aspects of management of recurrent aphthous stomatitis J Europ Acad Dermatol Venereol 21 2007 1019 1026
15. S. Delanian, and J.L. Lefaix Complete healing of severe osteoradionecrosis with treatment combining pentoxifylline, tocopherol and clodronate Br J Radiol 75 2002 467 469
16. S. Delanaian, S. Balla-Mekias, and J.-L. Lefaix Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol J Clin Oncol 17 1999 3283 3290
17. A. Lyons, and N. Ghazali Osteoradionecrosis of the jaws: current understanding of its pathophysiology and treatment Br J Oral Maxillofac Surg 46 2008 63-60
18. N.D. Futran, A. Trotti, and C. Gwede Pentoxifylline in the treatment of radiation-related soft tissue injury: preliminary observations Laryngoscope 107 1997 391 395
19. J.L. Fernandes, R.T. de Oliveira, R.L. Mamoni, O.R. Coelho, J.C. Nicolau, and M.H. Blotta Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease - A randomized placebo-controlled study Atherosclerosis 196 2008 434 442
20. M. Dion, D. Hussey, J. Doornbos, A. Vigliotti, B. Wen, and B. Anderson Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis Int J Radiat Oncol Biol Phys 19 1990 401 407
21. V. Lima, F.D. Vidal, F.A. Rocha, G.A. Brito, and R.A. Ribeiro Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats J Periodontol 75 2004 162 168
22. S. Delanian, and J.L. Lefaix The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway Radiother Oncol 73 2004 119 131
23. D. Tousoulis, C. Antoniades, C. Vassiliadou, M. Toutouza, C. Pitsavos, and C. Tentolouris Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure Eur J Heart Fail 7 2005 1126 1132
24. S.N. Han, D. Wu, W.K. Ha, A. Beharka, D.E. Smith, and B.S. Bender Vitamin E supplementation increases T helper 1 cytokine production in old mice infected with influenza virus Immunol 100 2000 487 493
25. M.J. Mol, Y.B. de Rijke, P.N. Demacker, and A.F. Stalenhoef Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment Atherosclerosis 129 1997 169 176
26. R. Houwing, M. Overgoor, M. Kon, G. Jansen, B.S. van Asbeck, and J.R. Haalboom Pressure-induced skin lesions in pigs: reperfusion injury and the effects of vitamin E J Wound Care 9 2000 36 40